Guidance for control of parvovirus B19 infection in healthcare settings and the community.
Interventions for parvovirus B19 infection need to balance the low risk of infection at a population level with the potential for serious adverse outcome for particular groups, notably the fetus, people with haemoglobinopathies and the immunocompromised. This guidance aims to assist the local decision-making process to be as evidence-based as the available evidence allows.
Crowcroft
N S
NS
Immunisation Division, Communicable Disease Surveillance Centre, London.
Roth
C E
CE
Cohen
B J
BJ
Miller
E
E
D000293:Adolescent; D000328:Adult; D002648:Child; D017714:Community-Acquired Infections / Q000517:prevention & control*; D003428:Cross Infection / Q000517:prevention & control*; D016731:Erythema Infectiosum / Q000517:prevention & control* / Q000635:transmission; D005260:Female; D017408:Guidelines as Topic; D006801:Humans; D017053:Infection Control / Q000592:standards*; D017758:Infectious Disease Transmission, Patient-to-Professional; D008297:Male; D016732:Parvovirus B19, Human / Q000302:isolation & purification*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D012307:Risk Factors; D006113:United Kingdom